We are pleased to announce that an application to support doctors and patients in the treatment of hypertension, developed by KII investee CureApp, has received a manufacturing and marketing approval (pharmaceutical approval) from the Ministry of Health, Labor and Welfare as of April 26, 2022. This is the first time in Japan and the first time in the world for a stand-alone software application to support doctors and patients to obtain a pharmaceutical approval, and the first time in the world for an application targeting hypertension.

CureApp Web site First in the world to obtain regulatory approval for an application that supports physicians and patients in the treatment of hypertension

Related URL
・CureApp